Press Releases

BIA responds to the House of Lords Science and Technology Committee report on the Life Sciences Industrial Strategy

The House of Lords Science and Technology Committee have published its report on the Life Sciences Industrial Strategy. The BIA submitted written evidence to the inquiry last Autumn and BIA CEO Steve Bates also gave oral evidence to the Committee. Today the BIA has responded to the release of the report.

New CBI Report - Smooth Operations - Highlights Importance Of Getting EU Rules Right For Life Sciences

CBI seeks to inform Brexit negotiations by outlining where British businesses want to stay close to EU rules and where they want divergence.

BioIndustry Association/Informa Biotech Financing Update shows venture capital financing and follow on financing are off to a solid start in 2018

The BIA/Informa Biotech Financing Update: December 2017-February 2018 released today shows that venture capital financing and follow on financings on the public markets are off to a solid start in 2018.

Statement in response to the EU Council ratifying the Brexit transition deal

The associations representing the European and British life science industry (AESGP, ABPI, BIA, BGMA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have today responded to the European Council approving terms of the transition period agreed between the UK Government and EU.


Member News

Cell and Gene Therapy Catapult opens manufacturing centre to accelerate growth of the industry in the UK

Business Secretary Greg Clark and Science Minister Sam Gyimah officially opened centre to ‘bridge the gap’ between scientific research and commercialisation of the medicines of the future. Over £60 million of Industrial Strategy investment is being used to develop the new centre.

Cobra Biologics Receives the Queen’s Award for Enterprise in International Trade

The UK’s most prestigious business award granted in recognition of outstanding achievement in the export of services for gene and immunotherapy products.

Synpromics awarded Innovate UK grant to evaluate its inducible promoter platform in collaboration with Lonza Pharma & Biotech

Synpromics announces a partnership with Lonza Pharma & Biotech to further develop its inducible promoter system and improve manufacturing of biopharmaceuticals. The project has been made possible through the award of a £235,000 grant from Innovate UK.

Driven by rapid growth Oxford Sciences Innovation expands to The Oxford Science Park

Oxford, UK, 19 April 2018 – Oxford Sciences Innovation (OSI), which invests in world-leading science and technology from the University of Oxford, is expanding at The Oxford Science Park, one of the UK's leading parks for science and technology companies.


BIA blog

BIA City and Finance Update April 2018

April was a mixed month – showing both the frailty and the strength of the bio-investing world. Also this month, we discuss IPOs and introduce the investor, Advent International – a private equity specialist.

Evolving Expectations – BIA Chief Medical Officer Summit 2018

The BIA Chief Medical Officer Summit was a new event held in early March aimed at supporting the skills required to be a CMO in an SME. Here, Dr Penny Ward, CMO of Karus Therapeutics, and vice-Chair of the BIA Science and Innovation Advisory Committee, takes a look at some of the highlights from the day.

CEO Update: Monday 23 April

It was great to see so many BIA members at the official opening of the Cell and Gene Therapy Catapult’s new GMP manufacturing centre in Stevenage today. The formalities were done by Business Secretary Greg Clark MP, and Science and Universities Minister Sam Gymiah MP, but what inspired me was the way in which UK SME engagement has been the hallmark of the project to this point. Initial collaborators Autolus, Cell Medica, AdaptImmune, Thermo Fisher Scientific as well as the Cell and Gene Therapy Catapult itself are BIA members so for me it’s fantastic to see the power of our community using the Industrial Strategy we’ve advocated to move this important part of our sector forward.

Video of the Week - Genomics Education Programme: Meet the Clinical Bioinformaticians

Clinical bioinformaticians work to make genome data clinically actionable; to make sense of large amounts of data so that other healthcare professionals can use it to inform decisions about diagnosis, treatment and care. They straddle the worlds of biology and computer programming to provide a vital link in the patient pathway. This film from the Genomics Education Programme showcases what the work of a clinical bioinformatician involves, the kind of traits and skills required, and some of the challenges facing both those working in the profession and the NHS more broadly.


Our publications

Please find a selection of featured BIA publications below. To see our full publications library, click here

Influencing and shaping our sector, BIA update: January - April 2018

This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry, from January to April 2018.

Biotech Financing Update: December 2017 to February 2018

The BIA/Informa Biotech Financing Update: December 2017-February 2018 released today shows that venture capital financing and follow on financing on the public markets are off to a solid start in 2018.

Pipeline Progressing: The UK's Global Bioscience Cluster in 2017

A new report released by the BioIndustry Association (BIA) and Informa Pharma Intelligence reveals that the UK has the strongest clinical and preclinical pipeline in Europe.

BIA Best practice guide for communicating R&D

Ensuring investors and the wider public are well informed and confident about bioscience is crucial to the success of individual companies and the sector as a whole. To support the sector to maintain high standards in communications about R&D progress, the BIA has produced a best practice guide for bioscience companies with a supporting library of resources.